SCHEMBL845304

SCHEMBL845304

CC(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)Cc3cccs3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845235 0.93 MAPK1 (0.52) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL13272192 0.93 MAPK1 (0.52) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL13272186 0.91 MAPK1 (0.51) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL845288 0.91 MAPK1 (0.51) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL845486 0.90 MAPK1 (0.50) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL844967 0.90 MAPK1 (0.50) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL844977 0.90 MAPK1 (0.50) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL12488611 0.85 ALDH1A1 (0.52) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL2179610 0.85 ALDH1A1 (0.52) MAPK1L3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL845154 0.84 ALDH1A1 (0.54) MAPK1ALDH1A1HTTNPSR1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed